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Background and objective 
Results of interventional trials in renovascular hypertension have been disappointing and medical 
therapy is the current recommended gold standard. However, the comparative long-term benefits of 
different antihypertensive drug classes in atherosclerotic renal artery stenosis are not known. We 
aim to assess the effect of different antihypertensive drug classes on outcomes in renovascular 
hypertension 
 
Design, setting, participants, and measurements 
Using Tayside Health Informatics Centre database, anonymised data over a 6-year period was 
analysed. Biochemistry, prescribing data, morbidity, mortality and demographic data were accessed 
via hospital medical records and electronic data stored in the Tayside Health Informatics Centre Safe 
Haven. General Registrar’s Office data was used to identify patients who died from cardiovascular 
disease. Independent predictors of survival in each group were analyzed using Kaplan-Meier survival 
curves and Cox proportional hazard models, adjusted for a range of covariates, using Time-Updated 
Drug Analysis. Blood pressure data was obtained from primary and secondary care clinic blood 
pressure records for each patient. Adjustments for mean systolic blood pressure over the follow-up 
period and baseline blood pressure were made. 
 
Results 
579 patients with Atherosclerotic Renal Artery Stenosis were identified. In the unilateral renal artery 
stenosis cohort, Calcium Channel Blockers but not ACE inhibitors/ARBs, were associated with a 
significant reduction in all-cause (HR=0.45, CI= 0.31, 0.65; P=<0.0001) and Cardiovascular ((HR= 0.51, 
CI =0.29-0.90 P=0.019). This was maintained after adjustment for blood pressure. In the bilateral 
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renal artery stenosis cohort, both classes of drugs reduced all-cause but not cardiovascular 
mortality. Patients with moderate disease benefitted more than those with mild or severe disease.  
 
Conclusions 
Calcium Channel Blockers are associated with significantly increased survival and lower 
cardiovascular mortality particularly in patients with moderate RAS disease.  
 
Introduction 
Atherosclerotic renal artery stenosis (ARAS) accounts for an estimated 90% of renovascular disease1 
and is often complicated by renovascular hypertension, chronic kidney disease (CKD)2 and increased 
adverse cardiovascular outcomes.  This increased risk of cardiovascular disease and subsequent high 
cardiovascular mortality has resulted in significant research on how best to approach the 
management of these patients3. Research efforts have largely focused on assessing the efficacy of 
renal artery revascularisation; however several randomised controlled trials (RCTs) have failed to 
demonstrate a clear benefit of this intervention over medical therapy4. Current guidelines suggest 
that in view of these trial results, medical management with antihypertensive therapy is the 
preferred option for patients with renovascular disease. Drugs that interrupt the renin-angiotensin-
aldosterone system (RAAS) are regarded as first line therapy in renovascular hypertension5. The 
value of angiotensin converting enzyme inhibitors (ACEi) may extend beyond antihypertensive 
properties as they protect against angiotensin II (ATII) induced cardiovascular damage, including left 
ventricular hypertrophy, vascular remodelling and activation of fibrogenic cytokines6. However, they 
reduce blood flow through the stenotic kidney and therefore while blood pressure may fall rapidly, 
there is often an ensuing deterioration in renal function7 . Dihydropyridine Calcium channel blockers 
(CCBs) in clinical use inhibit voltage-gated L-,T- and P-/Q type calcium channels to different degrees 
of selectivity8 and have beneficial effects on arterial smooth muscle relaxation without 
compromising renal function. Furthermore, CCBs have been shown to inhibit adverse vascular 
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remodelling9. However, none of  these drug classes have never been specifically trialled in a 
renovascular hypertension cohort and experimental evidence of their effect on the progression of 
renal damage has been previously debated10. 
Many patients with renovascular disease have treatment-resistant hypertension and therefore there 
remain significant challenges in the control of blood pressure, resulting in the use of multiple 
antihypertensive agents to achieve adequate control11. Surprisingly, no RCTs have investigated the 
comparative efficacy of various antihypertensive drug classes specifically in the management of 
renovascular hypertension. The aim of this study was to investigate the effect of two commonly 
used classes of antihypertensive agents, RAAS-blocking agents (ACEi and ARBs) and CCBs on 
progression of CKD, cardiovascular and all-cause mortality in Unilateral Renal Artery Stenosis (URAS) 
and Bilateral Renal Artery Stenosis (BRAS). 
 
Methods 
Study Population 
This was a retrospective population-based cohort study of all hypertensive patients within the 
population of Tayside, Scotland who underwent a Magnetic Resonance (MR) angiogram or 
Mercaptoacetyltriglycine(MAG)-3 scan for investigation of renovascular disease (n=579) between 
Jan 2005 and June 2012.  These were contemporaneous investigations of choice for renovascular 
disease based on local guidelines during the specified time window. Numbers of patients undergoing 
alternative imaging investigations were too small for inclusion. We excluded patients with no 
evidence of significant renovascular disease (<50% stenosis), with fibromuscular dysplasia, solitary 
kidney and those who had already undergone renal transplantation. Further exclusion criteria 
included ambiguous radiology reports, poor quality images precluding assessment of renal artery 
stenosis and dual RAAS therapy. These data were linked to biochemistry blood data, prescribing 
data, co-morbidity information, dates of medical or surgical interventions, demographic data and 
cause of death (GRO) data provided by Health Informatics Centre (HIC) in Tayside Scotland. The HIC 
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database contains information on all patients within Tayside who are registered with a General 
Practitioner (GP). Hospitalisations due to cardiovascular events were captured by linkage to the 
national hospital admissions Standardised Morbidity Record (SMR-01) data held by the Information 
Services Division of the National Health Service (NHS) and mortality data was provided by the 
National Records of Scotland (NRS). The SMR-01 captures all national public sector hospital 
admissions from 1981 onwards. Cardiovascular disease-related mortality was defined as death with 
an underlying ischaemic/CHD cause on the death certificate (ICD codes: ICD-9, 410–414; ICD-10 I20–
I25) or for cerebrovascular disease including transient cerebral ischaemic attacks and related 
syndromes (ICD-9 430–43; ICD-10 I60–I69 and G45). These ICD codes were chosen as they are used 
in the official national statistics for CVD12. Definitions of severity of stenosis based on convention 
used in radiological reports were as follows: mild = <50%, moderate = 50-80% and severe = >80%. 
ESRD was defined as the first reading of eGFR<15ml/min in during the follow-up period from the 
date of diagnosis of URAS or BRAS. eGFR was calculated from serum creatinine using the Modified 
Diet in Renal Disease (MDRD) equation. Longitudinal blood pressure data was obtained using clinic 
bp data recorded in both primary and secondary care medical records for each patient. 
 
Statistical analysis 
The primary outcome was defined as all-cause mortality and all major hospitalised cardiovascular 
disease (CVD)-related deaths after the date of diagnosis of ARAS. The secondary outcome was 
defined as time to end-stage renal disease (ESRD). The presence of atherosclerotic renovascular 
disease was itself an indicator of background vascular disease. 
 
For comparison of the baseline characteristics of the study population we used the chi-square test 
for categorical variables and t-tests for continuous variables. A value of P < 0.05 was considered 
statistically significant. Time updated cox proportional hazard models (R Software-3.4.1) were used 
to calculate all-cause mortality and CVD mortality associated with the use of each drug class. In 
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order to determine the robustness of the findings, we also examined patient survival stratified by 
severity of RAS, based on the hypothesis that those with severe RAS would have a higher mortality. 
These time updated Cox proportional hazard models were adjusted for age, sex, stent placement 
(yes/no), presence of diabetes, use of diuretics, statins, CCB, ACEi/ARB, beta-blockers and severity of 
RAS at baseline.  In order to test the assumption of proportional hazards we generated time-
dependent covariates by creating interactions of the predictors and a function of survival time and 
included these models.  ACEi/ARB, CCB and Thiazide Diuretics were modelled as time-dependent 
variables where the follow-up time was split into intervals of 60 days and drugs use in each of the 
interval was modelled prospectively. Thus, if in the interval 1 a patient was on ACEi, this patient 
would have added person years to the ACEi group. If the patient was switched to CCB in the next 
interval this patient would then add person years to CCB groups. Whereas, if the patient was on 
both ACEi or ARB and CCB in a particular interval, he would have added person years to both ACEi/ 
ARB and CCB groups.  To check for the effect of blood pressure, the average Mean Arterial Pressure 
over the duration of follow-up for each subject was calculated. 
 
Results 
Baseline characteristics of the study population 
Table 1 shows the baseline characteristics of the study population.  The study consisted of 394 cases 
with URAS and 148 cases with BRAS.  Those with BRAS were significantly more likely to have stent 
placement and had significantly higher all-cause and CVD mortality compared to those with URAS 
(Figure 1). Patients with URAS were also more likely to have a baseline prescription of CCB and ACEi 
or ARB. There were no differences in statin and aspirin exposure between groups.  
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Predictors of all cause and CVD related mortality in URAS and BRAS using time updated analysis 
In the study population 50.8 %( n=86/169) of patients with BRAS and 36.8% (n=151/410) patients 
with URAS died during the follow-up period for 3.5 years.  We utilised the longitudinal drug 
prescription data to investigate the effect of ACEi/ARB and CCB on all-cause and CVD related 
mortality in both URAS and BRAS patients.  
 
Calcium Channel Blockers 
In the time–updated analysis (Table 2) CCBs were significantly associated with increased overall 
survival in URAS (HR=0.45, CI= 0.31, 0.65; P=<0.0001) and BRAS (HR=0.39 CI= 0.22, 0.69; P=0.0013). 
CCBs also showed a protective effect of CVD related mortality in URAS (HR= 0.51, CI =0.29-0.90 
P=0.019) but not for BRAS (HR=0.47, CI= 0.22, 1.02, P=0.056). When the URAS and BRAS cohorts 
were combined, the results remained consistent. In the combined analysis CCB were significantly 
associated with lower all cause (HR=0.43 (0.32, 0.59) P<0.0001) and CVD mortality (HR=0.49 (0.31, 
0.78) P=0.0022) 
 
ACE inhibitors/ Angiotensin Receptor Blockers 
We found that use of ACEi/ARBs was not associated with all-cause mortality reductions in URAS 
(HR=0.70 (0.48, 1.00) P=0.05) cohort but was associated with reduced all-cause mortality in the BRAS 
cohort (HR=0.41(0.21, 0.80) P=0.009). However these classes of drugs were not associated with CVD 
related mortality in both URAS (p=0.80) or BRAS (p=0.20) populations.  In the combined analysis, 
(URAS and BRAS), ACEi/ARBs were associated with lower all-cause (HR=0.60 (0.44, 0.82) P=0.0016) 
but not CVD mortality (HR=0.73 (0.46,1.16) P=0.19).  
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Time updated analysis showed that increasing age, lower baseline eGFR, and increasing duration of 
diabetes were also independent predictors of survival in both URAS and BRAS.  Interestingly, statin 
and aspirin exposure made no statistically significant impact on all-cause or CVD mortality in URAS or 
BRAS cohorts in our study.  
 
Blood pressure effects 
To investigate if the protective effect of CCB on RAS was mediated by a better control of blood 
pressure we analysed a subset of patients for whom longitudinal blood pressure measurements 
were available (n=257 for URAS and n=88 for BRAS). After adjustments for mean arterial pressures in 
this small subset of patients, CCB continued to show a statistically significant reduction in all-cause 
mortality in URAS population (HR=0.42 CI= 0.23, 0.79; P=0.006) but not in BRAS population. The 
results were consistent for the ACEi/ARB cohort. This subset analysis also showed that lower MAP, 
lower baseline eGFR, and increasing duration of diabetes were independent predictors of survival in 
both URAS and BRAS.  
 
Severity of Stenosis 
Finally, we wanted to investigate if the protective effect of CCB varied according to the severity of 
stenosis and therefore could influence choice of therapy in patients with hypertension and different 
degrees of RAS.  We performed a time –updated analysis, stratified for severity of URAS. These 
showed that those with moderate stenosis (HR=0.14(0.05,0.39) P=0.0001) were mostly likely to 
benefit from CCB as compared to those with mild (HR=0.49(0.18,1.29) P=0.15) or severe stenosis 
((HR=0.69(0.42,1.13) P=0.14). The effect of ACEi on all-cause mortality in URAS did not vary by the 
severity of stenosis. Consistent with the findings13of the CORAL trial, stent insertion did not improve 
survival in either URAS or BRAS cohorts (Figure 2a and 2b). 
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Time to ESRD in URAS and BRAS 
In the study population consisting of both URAS and BRAS less than 5% patients developed ESRD. In 
the URAS and BRAS population combined there was no effect of ACEi/ARBs or CCB on delaying time 
to end-stage renal disease.  As expected, lower baseline eGFR (P<0.0001), higher age of diagnosis of 
(P=0.02) and the presence of diabetes (P=0.02) was associated with rapid progression to ESRD. In an 
analysis, stratified by URAS and BRAS subgroups no effect of ACEi/ARBs or CCB was seen.  
 
Discussion 
To the best of our knowledge, this is the first cohort head-to-head study comparing effects of two 
commonly used medical management strategies in hypertension on CVD and overall mortality in 
patients with URAS and BRAS. Furthermore, we included longitudinal blood pressure control data to 
examine the blood pressure effect of these drugs. The main finding of our study is that CCBs were 
associated with a statistically significant overall survival benefit in patients with URAS and BRAS. 
Treatment with CCBs was also shown to be associated with reduced CVD mortality and the beneficial 
effects of CCBs on all-cause mortality persisted in the time updated analysis when longitudinal blood 
pressure was accounted for. This beneficial effect was most pronounced in those with moderate 
stenosis as compared to mild or severe stenosis suggesting that optimal timing for therapy in ARAS is 
also an area that requires further research.  
 
Time-updated drug analysis did not show any effect of ACEi/ARBs on CVD mortality in patients with 
established renovascular disease, either with URAS or BRAS. There was a reduction in all-cause 
mortality in the BRAS but not URAS cohort on ACEi/ARBs. The all-cause mortality reduction in the 
combined cohort is likely to be driven by the reductions seen in the BRAS cohort. 
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There was no effect of the different drug classes on progression of CKD to ESRD in patients with 
URAS or BRAS. However, numbers of patients who progressed to ESRD were small. The management 
of ARAS remains controversial. Revascularisation was previously thought to be the mainstay of 
treatment but over the last few years large randomised controlled trials have favoured aggressive 
medical therapy. The 2009 Angioplasty and Stent for Renal Artery Lesions (ASTRAL) trial14 findings 
were reinforced by the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial in 
201413. Justifiably, these trials have shifted the focus of treatment back to medical therapy. Due to 
the lack of clinical trial evidence in ARAS specific cohorts, the management of hypertension in 
patients with ARAS has been extrapolated from other populations of patients with hypertension. 
RAAS blockade is being increasingly used in these patients followed by calcium channel blockers, 
thiazides and beta blockers. Use of RAAS blockade was, therefore, previously thought to be 
contraindicated due to concerns about precipitating a decline in renal function. However, there is 
evidence supporting both its ability to be used in patients with renovascular disease and improved 
survival15, 16. In this present study, we did not find a significant mortality benefit with RAAS blocking 
agents once patients had already developed URAS or BRAS. However, we did find both overall and 
CVD survival benefit with CCBs. We are unable to determine with certainty whether the benefits 
seen with CCBs are due to blood pressure reduction alone but our longitudinal bp data suggest that 
this is perhaps not the case. There is certainly good experimental evidence to suggest that CCB’s 
positively remodel vasculature in hypertension. Animal studies have suggested that dihydropyridine 
CCBs attenuate oxidative stress and enhance matrix metalloproteinase expression and activity9, 17. 
Other concerns regarding medical management include potential progression of stenosis and 
occlusion and damage caused by long-term ischaemia. Studies have shown that progression of URAS 
to ESRD is rare18, 19, often because cardiovascular events overtake progression to ESRD. This is in 
keeping with the findings of this present study. ` Our finding that patients with moderate stenosis 
benefitted most from CCB treatment would suggest that patients with established disease benefit 
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less from CCB therapy compared to those with mild RAS and therefore early institution of these 
drugs for hypertension as per current guidelines may have added benefits. 
 
A strength of our study is that we have examined effects of longitudinal blood pressure and anti-
hypertensive treatment according to whether patients have unilateral of bilateral renal artery 
stenosis. We have also used longitudinal drug prescription data to look at time updated analysis of 
the effect of treatment rather than examining baseline data alone. Large observational studies, 
conducted using large health care databases, can be affected by immortal time bias, which can 
create an impression of remarkable benefit for a drug20. However, the modelling of the longitudinal 
data using a time-updated analysis can control for this bias and helps avoid confounding by 
indication.  In this study we demonstrate the importance of using time-updated analysis as 
compared to baseline-only  analysis. Our baseline analysis showed a protective effect of ACEi/ARBs 
on survival in RAS, however, this disappeared when we modelled the drug exposure windows using 
time-updated analysis.   
 
As is common with all observational studies, our study may be subject to selection bias. However, 
we included all-comers within the stated timeframe. The lack of benefit observed in the BRAS group 
and CKD progression to ESRD may be due to small sample size and therefore lack of power. Another 
limitation of our study was that we used office blood pressure rather than the 24-hour Ambulatory 
blood pressure. However, it would not have been possible to obtain longitudinal bp if restricted to 
24-hour ABPM readings alone as ABPMs are not routinely used for follow –up in clinical practice. 
Another limitation in this study is that we are not able to adjust for longitudinal changes in dose of 
ACE/ARB and CCB.  Whilst we acknowledge the possibility of sub-optimal dosing – which might bias 
these results, our data reflects real world in clinical practice in which patients with RAS and 
hypertension are put on the maximum tolerable dose for CCB and ACE/ARB. 
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The evidence base surrounding the use of anti-hypertensive medication in patients with 
renovascular disease is lacking and further evidence is required to guide medical management. Our 
study demonstrates the benefit of treatment of hypertension with CCBs in patients with URAS and 
BRAS and should provide clinicians with confidence in using this drug in patients with RAS. We would 
not advocate stopping the prescribing of RAAS blocking agents in patients with URAS or BRAS based 
on the results of this study alone. Further larger datasets should be analysed to confirm or refute 
these findings. In conclusion, we have demonstrated an overall and CVD survival benefit of 
treatment with CCBs in patients in patients with both URAS and BRAS. These results require 
confirmation in the form of prospective randomized controlled trials. As increasing evidence guides 
clinicians away from revascularisation, clarification of the optimal anti-hypertensive treatment 
combination is required in order to guide medical management in this high risk group of patients. 
 
Disclosures: None of the authors have any disclosures directly related to the information presented 
in the manuscript. 
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Table 1: Demographic and clinical characteristics of study population 
  URAS(394) BRAS (148) P-value 
Age at diagnosis (years) 75.3(SD9.1) 76.6(SD8.7)  NS 
Sex (Males) n, (%) 205 (52%) 83 (56%)  0.96 
Mean Duration of Follow-up (y) 3.5 (SD2.02) 3.3 (SD2.04)  0.8 
Stent insertion 22% 42% <0.0001 
% Type II Diabetes 36% 37% 0.9 
% Death 36% 50%  <0.0001 
% ESRD 14% 11% 0.81 
% CVD 40% 50% 0.001 
% ACEi or ARBs 9% 6%  0.75 
% Thiazide Diuretics 3% 4%  0.80 
%CCB 30% 22%  0.01 
%Statin 50% 52% 0.90 
Mean SBP 145.60 (SD 16.74) 144.13(SD 15.82)  0.46 
eGFR 34.2 (SD 11.9)  33.2 (SD 11.5)  0.43 
 
ESRD=End Stage Renal Disease; CVD=Cardiovascular Disease; ACEi= Angiotensin Converting Enzyme inhibitor; ARBs=Angiotensin Receptor Blockers; CCB= 
Calcium Channel Blocker; eGFR=estimated Glomerular Filtration Rate: Mean BP: Mean blood pressure during the follow-up period 
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Table 2A: Predictors of survival on URAS and BRAS using time-updated analysis of ACEi/ARBs and 
CCB 
 
 
URAS BRAS URAS/BRAS combined 
 
HR 95%CI p HR 95% CI p HR 95% CI p 
Age 1.04 1.01,1.06 0.001 1.04 1.01,1.08 0.02 1.04 1.02,1.06 <0.0001 
CCB 0.45 0.31,0.65 <0.0001 0.39 0.22,0.69 0.0013 0.43 0.32,0.59 <0.0001 
ACEi/ARBs 0.69 0.48,1.00 0.05 0.41 0.21,0.80 0.0088 0.60 0.44,0.82 0.0016 
Baseline 
eGFR 0.97 0.96,0.98 <0.0001 0.97 0.95,0.99 0.0025 
 
0.97 
 
0.96,0.98 
 
<0.0001 
Diabetes 1.06 0.64,1.75 0.82 0.52 0.22,1.20 0.12 0.84 0.55,1.29 0.43 
Duration of 
Diabetes 1.04 1.00,1.07 0.025 1.07 1.025,1.12 0.0025 
 
1.05 
 
1.02,1.07 
 
0.0004 
 
Table 2B: Predictors of survival on URAS and BRAS using time-updated analysis of ACEi/ARBs and 
CCB, including average Mean Arterial Pressure over follow-up 
 
URAS BRAS URAS/BRAS 
 
HR 95%CI p HR 95% CI p HR 95% CI p 
Age 1.03 0.99,1.07 0.11 1.02 0.95,1.09 0.59 1.03 1,1.07 0.048 
CCB 0.42 0.23,0.79 0.0065 0.60 0.25,1.44 0.25 0.46 0.28,0.77 0.0026 
ACEi/ARBs 0.64 0.36,1.17 0.15 0.21 0.07,0.67 0.0066 0.49 0.29,0.82 0.0067 
Baseline 
eGFR 0.96 0.94,0.98 <0.0001 0.93 0.88,0.97 0.00069 
0.96 0.94,0.97 <0.0001 
Diabetes 1.21 0.50,2.93 0.67 0.60 0.17,2.08 0.42 1.03 0.50,2.13 0.93 
Duration of 
Diabetes 1.07 1.02,1.12 0.0089 1.07 1.00,1.14 0.046 
1.07 1.03,1.11 0.0012 
Avg MAP 0.96 0.93,0.99 0.011 0.96 0.91,1.00 0.074 0.97 0.94,0.99 0.0084 
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Figure 1: Mortality in URAS vs BRAS 
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Figure 2a: Effect of Stent on survival on URAS 
 
 
Figure 2b: Effect of Stent on survival on BRAS 
 
 
 
 
